Loading clinical trials...
Loading clinical trials...
A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Tiotropium 18 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Conditions
Interventions
Umeclidinium
Umeclidinium matching placebo
+2 more
Locations
99
United States
GSK Investigational Site
Spartanburg, South Carolina, United States
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
St. John's, Newfoundland and Labrador, Canada
GSK Investigational Site
Truro, Nova Scotia, Canada
Start Date
September 1, 2014
Primary Completion Date
May 25, 2015
Completion Date
June 15, 2015
Last Updated
January 24, 2018
NCT06712563
NCT07518472
NCT06831994
NCT05730088
NCT02755974
NCT07363980
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions